ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2025
Resveratrol and caffeic acid attenuate diet-induced obesity by inhibiting the SREBP-1/ACLY lipogenic axis in adipose tissue of rats.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New insights into the ACLY-mediated metabolic and epigenetic interplay in macrophages.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Caffeic Acid and Human Health: Evidence-Based Roles in Disease Prevention and Treatment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a health problem with an economic burden. This study examined the anti-obesogenic impact of caffeic acid (Caf) or resveratrol (Res) and their effect on lipogenic enzymes. Wister albino rats received high-fat diet (HFD) for 16 weeks then were randomly allocated into three groups and treated orally with either drug vehicle, Caf (50 mg/kg/day) or Res (120 mg/kg/day) for further 6 weeks. Rats in control group received normal chow diet for 22 weeks. Treatment of obese rats with either Caf or Res attenuated body weight gain and fat pad mass, and improved hyperglycemia and dyslipidemia. Both drugs promoted adiponectin expression, while decreased tumor necrosis factor-alpha (TNF-α) levels in white adipose tissue (WAT) of obese rats. Res down-regulated the expression of sterol regulatory element binding protein-1 (SREBP-1) mRNA and protein levels of ATP citrate lyase (ACLY) and fatty acid synthase (FAS), to a greater extent than Caf. Conversely, both drugs promoted adipose triglyceride lipase (ATGL)-mediated lipolysis in obese rats and the effect of Res was superior to that of Caf. These findings suggest that Caf and Res have certain regulatory effects regarding obesity-related metabolic disorders, more likely through modulating lipogenesis and lipolysis-related proteins.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.